Five-year serological and clinical evolution of chronic Chagas disease patients in Cochabamba, Bolivia

Simple item page
dc.contributor.authorJimy Pinto
dc.contributor.authorMalia Skjefte
dc.contributor.authorJulio Alonso-Padilla
dc.contributor.authorDaniel Franz Lozano Beltrán
dc.contributor.authorLilian Pinto
dc.contributor.authorAina Casellas
dc.contributor.authorMery Elena Arteaga Terrazas
dc.contributor.authorKaren Galindo
dc.contributor.authorRoxana Challapa Quechover
dc.contributor.authorMaría Escobar Caballero
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:24:29Z
dc.date.available2026-03-22T14:24:29Z
dc.date.issued2023
dc.descriptionCitaciones: 5
dc.description.abstractThe study confirms that follow-up of benznidazole-treated T. cruzi-infected patients should be longer than five years to determine, with current tools, if they are cured. In terms of serological evolution, the single use of a total antigen ELISA might be a more reliable measure and suffice to address infection status, at least in the region of Bolivia where the study was done. Additional work is needed to develop a test-of-cure for an early assessment of drugs´ efficacy with the aim of improving case management protocols.
dc.identifier.doi10.1371/journal.pntd.0011498
dc.identifier.urihttps://doi.org/10.1371/journal.pntd.0011498
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/46334
dc.language.isoen
dc.publisherPublic Library of Science
dc.relation.ispartofPLoS neglected tropical diseases
dc.sourceFundación para el Desarrollo de la Ecología
dc.subjectBenznidazole
dc.subjectSerology
dc.subjectChagas disease
dc.subjectNifurtimox
dc.subjectTrypanosoma cruzi
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectClinical trial
dc.subjectDisease
dc.subjectObservational study
dc.titleFive-year serological and clinical evolution of chronic Chagas disease patients in Cochabamba, Bolivia
dc.typearticle

Files

Collections

Artículo Científico Publicado